Subjects | AA | AB | BB | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
Number | % | Number | % | Number | % | ||||||
Controls (n=99) | 8 | 8.1 | 42 | 42.4 | 49 | 49.5 | |||||
B27 positive controls (n=46) | 3 | 6.5 | 21 | 45.7 | 22 | 47.8 | |||||
B27 positive controls, DR4 negative (n=38) | 3 | 7.9 | 18 | 47.4 | 17† | 44.4† | |||||
SpA (n=172) | 12 | 7.0 | 64 | 37.2 | 96 | 55.8 | |||||
Ankylosing spondylitis (n=141) | 9 | 6.4 | 52 | 36.9 | 80 | 56.7 | |||||
SpA, without peripheral arthritis and uveitis (n=79) | 6 | 7.6 | 32 | 40.5 | 41 | 51.9 | |||||
SpA, DR4 negative (n=119) | 10 | 8.4 | 49 | 41.2 | 601-150 | 50.41-150 | |||||
SpA, DR4 positive (n=53) | 2 | 3.8 | 15 | 28.3 | 361-150 † | 67.91-150 † | |||||
SpA and peripheral arthritis (n=72) | 5 | 6.9 | 27 | 37.5 | 40 | 55.6 | |||||
SpA and peripheral arthritis, DR4 negative (n=52) | 5 | 9.6 | 21 | 40.4 | 26 | 50.0 | |||||
SpA and uveitis (n=46) | 2 | 4.4 | 16 | 34.8 | 28 | 60.9 | |||||
SpA and uveitis, DR4 negative (n=30) | 2 | 6.7 | 13 | 43.3 | 15 | 50.0 | |||||
SpA, peripheral arthritis and uveitis (n=25) | 1 | 4.0 | 11 | 44.0 | 13 | 52.0 | |||||
SpA, peripheral arthritis and uveitis, DR4 negative (n=16) | 1 | 6.3 | 9 | 56.3 | 6 | 37.5 |
↵1-150 p = 0.04; odds ratio 2.08; 99% confidence intervals (0.8, 8.15); π = 30%. † p = 0.03; odds ratio 2.62; 99% confidence intervals (0.78, 8.79); π = 27%.